A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Subjects With Poor Prognosis Hepatocellular Carcinoma.
Shawn YuMenggang YuBarry KeaneDavid M MauroPaul R HelftWilliam P HarrisHanna K SanoffMatthew S JohnsonBert O'NeilAutumn Jackson McReeAshwin S SomasundaramPublished in: The oncologist (2024)
In patients with localized, poor prognosis HCC, pembrolizumab in addition to glass Y90 radioembolization demonstrated promising efficacy and safety consistent with prior observations (ClinicalTrials.gov Identifier: NCT03099564; IRB Approved: 16-3255 approved July 12, 2016).